Javascript is currently disabled in your browser. Several features of this site will not function whilst javascript is disabled.
open access to scientific and medical research
Papers Published
Open access peer-reviewed scientific and medical journals.
Learn more
Dove Medical Press is a member of the OAI.
Learn more
Bulk reprints for the pharmaceutical industry.
Learn more
We offer real benefits to our authors, including fast-track processing of papers.
Learn more
Register your specific details and specific drugs of interest and we will match the information you provide to articles from our extensive database and email PDF copies to you promptly.
Learn more
Back to Journals » Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy » Volume 15
Authors Panjaitan NSD , Lestari CSW , Maha MS
Received 28 November 2022
Accepted for publication 1 December 2022
Published 14 December 2022 Volume 2022:15 Pages 3889—3890
DOI https://doi.org/10.2147/DMSO.S399410
Checked for plagiarism Yes
Editor who approved publication: Prof. Dr. Juei-Tang Cheng
Novaria Sari Dewi Panjaitan, Christina Safira Whinie Lestari, Masri Sembiring Maha
Center for Biomedical Research, Research Organization for Health, National Research and Innovation Agency (BRIN), Cibinong Science Center, Cibinong, West Java, Indonesia
Correspondence: Novaria Sari Dewi Panjaitan, Center for Biomedical Research, Research Organization for Health, National Research and Innovation Agency (BRIN), Cibinong Science Center, Jl. Raya Bogor No. 490, Km. 46, Cibinong, West Java, Indonesia, Email [email protected]
View the original paper by Dr Dzięgielewska-Gęsiak and colleagues
Diabetes mellitus is one of metabolic diseases characterized by the elevated blood glucose levels. There are growing studies regarding the effect of diabetes to the development of other diseases such as hypertension, stroke, and even blindness. In the study performed by Dzięgielewska-Gęsiak et al, the comparison of two different treatments in diabetic type-2 patients regarding the effect to the microbiota composition was shown and discussed. Their study compared the microbiota profile in patients treated by metformin only and metformin supplemented with insulin. This study is an interesting and informative study, which gives a novel idea and hint of the different pattern of microbiota composition as the effect of different treatments given to patients. However, certain suggestions are given to the authors as consideration for their future studies.
The alteration of homeostatic gut microbiota composition has been continuously reported to play important role in the health field, especially in metabolic diseases, such as diabetes mellitus.1 The study performed by Dzięgielewska-Gęsiak, et al, compared the profile of gut microbiota of the patients with diabetes mellitus type-2 given by two different treatments, metformin or metformin and insulin.2 Their results showed that there were no significant differences in the gut microbiota profile detected and analyzed from the patients treated with metformin compared to those treated with metformin and insulin. A question addressed here was why and how? Were the patients included in this study maintaining significant diet and life circumstances for that long time? Does insulin as a hormonal agent really do nothing in the gut microbiota alteration? Meanwhile, the microbiota composition was reported as one of the essential aspects in the development of metabolic diseases and one of factors causing the metabolic disorders itself, in which diabetes mellitus is included.3
After a deep reading, we provided several suggestions for the authors of this study or even for other scientists in the field as worth considering suggestions for being hopefully unraveled in the future studies. The long term treatment with metformin only or metformin+insulin, based on this particular study, caused no significant effect on the gut microbiota profile of the patients whom got the treatment for more than five years. However, there could be significant differences in gut microbiota profile if being compared to patients whom were just recently being treated with metformin. The comparison of gut microbiota profile could have been performed in comparing those in patients treated with metformin and other different anti-diabetic agent (treatment).
The abundant bacteria found in the undertreatment type-2 diabetic patients were Clostridiales, Firmicutes and Verrucomicrobia. Meanwhile, Bacteroidetes and Proteobacteria were in the smaller total proportions. In previous study, Bacteroidetes was reported to be associated with the high risk of diabetes mellitus while being compared to the microbiota composition of healthy individuals.4 The profile of Bacteroidetes in both groups of patients treated by metformin or metformin+insulin was low in this study, probably due to the effect of the anti-diabetic drug. Anyways, the role of insulin addition under metformin in altering the gut microbiota composition to the healthy composition for type-2 diabetes mellitus cases was not completely unraveled in this study. Therefore, these aspects could be revealed in the future studies.
Full acknowledgements are conveyed to all supports given to all authors of the study commented in this letter during the study period. The authors also would like to appreciate Dr. Sunarno, the Head of Center for Biomedical Research in National Research and Innovation Agency (BRIN) for his continuous support during the letter manuscript preparation.
NSDP went through the cited publications and analyzed the reported data. NSDP designed and conceived the critical design of the letter. NSDP wrote the original letter draft. CSWL and MSM recommended required corrections. NSDP, CSWL and MSM did necessary revision for improvement of the manuscript accordingly.
The authors report no conflicts of interest in this communication.
1. Nikolic DM, Ranin LT, Stojanovic MM, Ilic ID, Gostiljac DM, Soldatovic IA. Homeostatic microbiome disruption as a cause of insulin secretion disorders. Candida albicans, a new factor in pathogenesis of diabetes A STROBE compliant cross-sectional study. Med. 2022;101(45):e31291. doi:10.1097/MD.0000000000031291
2. Ahmad A, Yang W, Chen G, et al. Analysis of gut microbiota of obese individuals with type 2 diabetes and healthy individuals. PLoS One. 2019;14(12):1–15. doi:10.1371/journal.pone.0226372
3. Ye J, Wu Z, Zhao Y, Zhang S, Liu W, Su Y. Role of gut microbiota in the pathogenesis and treatment of diabetes mullites: advanced research-based review. Front Microbiol. 2022;13:1–13. doi:10.3389/fmicb.2022.1029890
4. Wang J, Li W, Wang C, et al. Enterotype bacteroides is associated with a high risk in patients with diabetes: a pilot study. J Diabetes Res. 2020;2020:1–11. doi:10.1155/2020/6047145
© 2022 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.
Contact Us • Privacy Policy • Associations & Partners • Testimonials • Terms & Conditions • Recommend this site • Top
Contact Us • Privacy Policy
© Copyright 2022 • Dove Press Ltd • software development by maffey.com • Web Design by Adhesion
The opinions expressed in all articles published here are those of the specific author(s), and do not necessarily reflect the views of Dove Medical Press Ltd or any of its employees.
Dove Medical Press is part of Taylor & Francis Group, the Academic Publishing Division of Informa PLC
Copyright 2017 Informa PLC. All rights reserved. This site is owned and operated by Informa PLC ( “Informa”) whose registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
In order to provide our website visitors and registered users with a service tailored to their individual preferences we use cookies to analyse visitor traffic and personalise content. You can learn about our use of cookies by reading our Privacy Policy. We also retain data in relation to our visitors and registered users for internal purposes and for sharing information with our business partners. You can learn about what data of yours we retain, how it is processed, who it is shared with and your right to have your data deleted by reading our Privacy Policy.
If you agree to our use of cookies and the contents of our Privacy Policy please click ‘accept’.